Grant PM - Search Results

1

Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Liang EC, Sceats L, Bayless NL, Strauss-Albee DM, Kubo J, Grant PM, Furman D, Desai M, Katzenstein DA, Davis MM, Zolopa AR, Blish CA. Liang EC, et al. Among authors: grant pm. J Virol. 2014 Aug;88(15):8629-39. doi: 10.1128/JVI.01257-14. Epub 2014 May 21. J Virol. 2014. PMID: 24850730 Free PMC article.

2

Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.

Grant P, Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen C, Harrington R, Kempf D, Zolopa A. Grant P, et al. Antimicrob Agents Chemother. 2008 Nov;52(11):4050-6. doi: 10.1128/AAC.00605-08. Epub 2008 Aug 18. Antimicrob Agents Chemother. 2008. PMID: 18710915 Free PMC article.

3

Antiretroviral rounds. Immediate ART after an OI: are we there yet?

Grant P, Zolopa A, Landovitz RJ. Grant P, et al. AIDS Clin Care. 2008 Sep;20(9):74-5. AIDS Clin Care. 2008. PMID: 18841619 No abstract available.

4

Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

Grant P, Zolopa A. Grant P, et al. J HIV Ther. 2008 Jun;13(2):36-9. J HIV Ther. 2008. PMID: 18953272 Review. No abstract available.

5

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A. Grant P, et al. Clin Infect Dis. 2009 Mar 1;48(5):680-2. doi: 10.1086/597008. Clin Infect Dis. 2009. PMID: 19191657 Clinical Trial.

6

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.

Grant P, Zolopa A. Grant P, et al. Curr HIV/AIDS Rep. 2009 May;6(2):63-7. doi: 10.1007/s11904-009-0010-3. Curr HIV/AIDS Rep. 2009. PMID: 19358776 Review.

7

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. Grant PM, et al. J Clin Virol. 2009 Dec;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. Epub 2009 Oct 12. J Clin Virol. 2009. PMID: 19819183 Free PMC article.

8

The use of resistance testing in the management of HIV-1-infected patients.

Grant PM, Zolopa AR. Grant PM, et al. Curr Opin HIV AIDS. 2009 Nov;4(6):474-80. doi: 10.1097/COH.0b013e328331c14f. Curr Opin HIV AIDS. 2009. PMID: 20048713 Review.

9

International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR. Grant PM, et al. Antimicrob Agents Chemother. 2010 Apr;54(4):1520-5. doi: 10.1128/AAC.01380-09. Epub 2010 Feb 1. Antimicrob Agents Chemother. 2010. PMID: 20124005 Free PMC article.

10

Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.

Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Talbot A, et al. Antimicrob Agents Chemother. 2010 Jun;54(6):2473-9. doi: 10.1128/AAC.00096-10. Epub 2010 Apr 5. Antimicrob Agents Chemother. 2010. PMID: 20368406 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters